FDA Panel’s Rejection of MDMA Is ‘Speed Bump, Not Stop Sign,’ for Psychedelic Industry

The psychedelic industry learned important lessons when a Food and Drug Administration advisory committee voted to reject a landmark MDMA-based therapy designed to treat PTSD. The rejection shook investors and demonstrates that FDA approval for novel psychedelic drugs is further away than previously thought, but industry insiders remain confident in the industry’s long-term success. The […]

Psychedelics, Virtual Reality Offer Novel Paths for Treating Eating Disorders 

Eating disorders have among the highest mortality rates of any psychiatric illness and remission rates among patients with eating disorders are, by some estimates, as low as 29%. New treatment modalities are urgently needed to improve outcomes, especially for people with severe and enduring eating disorders, industry insiders told Behavioral Health Business. Despite this, funding […]

Psychedelic Venture Studio Beckley Waves Acquires Ketamine Provider Nue Life

Psychedelic-focused venture studio Beckley Waves has acquired digital ketamine-assisted therapy (KAT) provider Nue Life. Beckley Waves seeks to improve access to well-being-enhancing medicines and tools in an industry that is dominated by “antiquated” approaches to mental health, according to Daniel Love, co-founder and partner at Beckley Waves and interim CEO of Nue Life. “At the […]

COMPASS Pathways Signals Confidence in Psychedelics with $285M in Funding

London-based COMPASS Pathways plc (Nasdaq: CMPS) has secured $285 million in private funding to advance the company toward offering psychedelics as a treatment for mental health conditions. The company appears to see a clear path toward FDA approval and has convinced several investors of the opportunity. COMPASS Pathways named 11 investment firms and hinted at […]

FDA’s Draft Guidance for Psychedelic Research Could Pave Way for More Widespread Adoption

The FDA is looking to hammer out a new pathway for studying the use of psychedelic drugs to treat behavioral health conditions. Specifically, the agency recently released a new draft guidance for the clinical development of psychedelic drugs. Although psychedelic drugs have shown promise in treating various mental health and substance use disorders, researchers have […]

Trauma-Focused Provider Stella Buys US Assets of Ketamine Company Field Trip

Chicago-based mental health care provider Stella has acquired the majority of ketamine-assisted therapy provider Field Trip Health & Wellness Ltd’s U.S. assets. The deal gives Stella a new line of business which its CEO says complements its existing offerings. Plus, the combined Stella-Field Trip assets will generate higher revenue and lower overhead than Field Trip […]

Psychedelics Must Be Based in ‘Traditional Psychiatric’ Care

For all the hype, psychedelics such as MDMA or psilocybin won’t succeed as a treatment or service line without substantial clinical support within behavioral health organizations. As recent ketamine-provider stumbles demonstrate, simply establishing access to and attempting to scale singular forms of treatment tend to lead to failure. Further, such treatment-specific ventures fail to address […]

Study: IV Ketamine As Good As The ‘Gold Standard’ For Resistant Depression

Researchers pitted ketamine therapy against electroconvulsive therapy (ECT) — the so-called “gold standard” intervention for severe depression. The study found that ketamine held its own. Six months after the treatments, about half (55%) of ketamine participants experienced at least a 50% improvement in depression symptoms and quality of life measures. That number was 41% for […]